This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Hair Loss Prevention Stack
Topical Anti-Androgen / DHT Blockade / Follicle Reactivation
Overview
What is Hair Loss Prevention Stack?
Sean's recommended early-intervention topical stack for androgenetic alopecia (AGA). The thesis: catch hair loss BEFORE follicle miniaturization completes, and use topical-only chemistry as the first line — keeping systemic 5-AR inhibitors (finasteride/dutasteride) as a second line if topicals fail. The stack pairs a topical androgen-receptor (AR) antagonist (RU-58841 OR CB-03-01 OR Topilutamide — these are substitutes, pick one) with PP-405 as a complementary follicle stem-cell reactivator that addresses dormant follicles via a different mechanism entirely.
Key Benefits
Local AR blockade at the scalp without systemic anti-androgen exposure (avoiding the post-finasteride syndrome / sexual side-effect risk window) plus, optionally, reactivation of dormant follicles via PP-405's mitochondrial-pyruvate-carrier inhibition. Best suited to early-to-moderate AGA where follicles are miniaturized but not yet scarred. All four compounds are research-use-only (RUO); none are FDA-approved for hair loss as of 2026 (CB-03-01 is FDA-approved as Winlevi for acne, not AGA).
Mechanism of Action
Two parallel mechanism layers. Layer 1 (pick one AR antagonist): RU-58841 / CB-03-01 / Topilutamide all competitively bind to scalp dermal-papilla androgen receptors, blocking DHT and testosterone from triggering follicle miniaturization. They differ in systemic-exposure profile — RU-58841 has community reports of systemic absorption and palpitations; CB-03-01 (clascoterone) and Topilutamide (fluridil) are designed to inactivate rapidly upon entering systemic circulation, giving them cleaner safety profiles. Layer 2 (complement): PP-405 inhibits the mitochondrial pyruvate carrier (MPC) in hair-follicle stem cells, forcing a metabolic switch from oxidative phosphorylation to glycolysis/lactate production — a state shown by Lowry/Christofk (UCLA) to push dormant follicles back into anagen (active growth) phase. Different molecular target, complementary clinical effect.
▸ Application protocol Topical
- 1 Cleanse + dry skin. Pat skin dry; wait 15-20 min after washing for retinoids (reduces irritation). Skin must be fully dry — moisture amplifies penetration and irritation.
- 2 Pea-sized amount (or thin layer) for the entire treatment area. More is not better — irritation scales faster than efficacy.
- 3 Layering rules. Avoid combining with benzoyl peroxide (degrades retinoids), AHAs, or salicylic acid in the same routine. Niacinamide and ceramides are safe co-applications.
- 4 Sunscreen mandatory next AM. Most topicals (especially retinoids, hydroquinone) increase photosensitivity. SPF 30+ broad-spectrum minimum.
- 5 Ramp slowly. Start every-other-night for 2-4 weeks; increase to nightly only after tolerance builds. Skipping a night during peak irritation is the right move.
No systemic dosing required — topicals act locally with minimal serum absorption at standard doses.
What to Expect
- Week 1-2Application protocol established. Watch for irritation.
- Week 4Early visible/measurable change. Most topicals are slow.
- Week 8-12Meaningful effect window for most topical actives.
- Month 6+Maintenance phase. Stopping reverses gains over weeks-months.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.